Correction

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer (vol 21, 135, 2019)

BREAST CANCER RESEARCH (2020)

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer (vol 21, 135, 2019)

Discover Peeref hubs

Publish scientific posters with Peeref

导出引文

分享论文